Is there scope for better individualisation of anthracycline cancer chemotherapy?

Anthracyclines are used to treat solid and haematological cancers, particularly breast cancers, lymphomas and childhood cancers. Myelosuppression and cardiotoxicity are the primary toxicities that limit treatment duration and/or intensity. Cardiotoxicity, particularly heart failure, is a leading cau...

Celý popis

Podrobná bibliografia

Vydané v:	British journal of clinical pharmacology Ročník 87; číslo 2; s. 295 - 305
Hlavní autori:	Sallustio, Benedetta C., Boddy, Alan V.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England 01.02.2021
Predmet:	anthracycline cancer cardiotoxicity individualised therapy pharmacogenetics pharmacokinetics pharmacokinetics cardiotoxicity cancer anthracycline pharmacogenetics individualised therapy
ISSN:	0306-5251, 1365-2125, 1365-2125
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!